This site provides INTERCEPT product information for International audiences Select your region
If you are not ensuring complete elimination of contaminating bacteria there will always be the risk of transfusion transmitted bacterial infection through platelet components and the chance of a septic transfusion reaction. Given that transfusion transmitted bacterial infection and septic transfusion reaction remain the principle causes of mortality related to transfusion, we thought it is our duty to address this blood safety risk in greater depth.
Want to stay updated on the latest pathogen inactivation news?
You can receive our highlights by subscribing to our newsletter.
Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.
Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.
© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0